首页> 外文期刊>Artificial cells, nanomedicine, and biotechnology. >MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/β-catenin pathway by targeting phospholipase D1
【24h】

MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/β-catenin pathway by targeting phospholipase D1

机译:MiR-638通过靶向磷脂酶D1通过wnt /β-catenin途径抑制口腔鳞状细胞癌的进展

获取原文
       

摘要

Objective: The current study aimed to explore the function of miR-638 on the progression of oral squamous cell carcinoma (OSCC) and relevant molecular mechanisms. Methods: Expression profile of miR-638 in OSCC tissues and cells was detected using quantitative real-time polymerase chain reaction (qRT-PCR) method. Chi-square test was performed to estimate the relationship between miR-638 and clinical parameters of OSCC cases. Cell viability and motility abilities were estimated using MTT and transwell assays, respectively. Potential targets of miR-638 in OSCC were identified through bioinformatics analysis and luciferase reporter assay. Results: MiR-638 exhibited decreased expression in OSCC tissues and cells, compared to non-cancerous controls ( P ?.05 for both). Moreover, its down-regulation was closely correlated with lymph node metastasis ( P =?.044) and TNM stages ( P =?.001). Enforced miR-638 expression reduced cell proliferation, migration and invasion, while its knockdown exhibited opposite effects. Phospholipase D1 ( PLD1 ) was confirmed as a target of miR-638 in OSCC. MiR-638 could inhibit wnt/β-catenin pathway through targeting PLD1 , thus realizing its anti-tumour action in OSCC. Conclusion: MiR-638 may be a tumour suppressor in OSCC by targeting PLD1 /Wnt/β-catenin pathway.
机译:目的:本研究旨在探讨miR-638在口腔鳞状细胞癌(OSCC)进展中的功能及相关分子机制。方法:采用定量实时聚合酶链反应(qRT-PCR)方法检测miR-638在OSCC组织和细胞中的表达情况。进行卡方检验以评估miR-638与OSCC病例临床参数之间的关系。分别使用MTT和transwell测定法估计细胞活力和运动能力。通过生物信息学分析和荧光素酶报告基因分析鉴定了miR-638在OSCC中的潜在靶标。结果:与非癌性对照相比,MiR-638在OSCC组织和细胞中的表达降低(两者均P <0.05)。此外,其下调与淋巴结转移(P = ?. 044)和TNM分期(P = ?. 001)密切相关。增强的miR-638表达减少了细胞的增殖,迁移和侵袭,而其敲低表现出相反的作用。磷脂酶D1(PLD1)被确认为OSCC中miR-638的靶标。 MiR-638可通过靶向PLD1抑制wnt /β-catenin途径,从而在OSCC中实现其抗肿瘤作用。结论:MiR-638可能通过靶向PLD1 / Wnt /β-catenin途径来抑制OSCC肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号